As expected, all tumors attaining a CR- regardless of molecular subtype- showed significantly higher levels of cell lineage markers (CD4, CD8 and CD20) as well as immune-activating (IGKC, CXCL9, CCL5, CXCL13) and immunosuppressive markers (IDO1, PD1), suggesting a greater infiltration of immune cells High tumor-infiltrating lymphocytes (TILs) levels have been associated with increased CR rates in ER+ HER2+/- tumors [18] and also in TNBC [19]. The gene discussed is CXCL9; the disease is neoplasm.